Lithium-ion batteries. Solar panels. Steel. Shipbuilding. Drones. The pattern is familiar enough that it should no longer surprise anyone. China identifies a strategic industry, floods it with state capital, undercuts competitors, and waits. The surprise this time is the industry: biotech and pharmaceuticals.
Morgan Stanley predicts that by 2040, a third of all FDA-approved drugs could originate from China. That single figure deserves to sit on the page for a moment before anyone reaches for a reassuring qualifier.
The pipeline works like this: biotech companies discover new drug candidates; Big Pharma then attempts to develop them into medicines that clear the Food and Drug Administration. If Chinese companies come to dominate the discovery end of that pipeline, they will hold something more consequential than market share. They will hold the power to decide which diseases get studied, which compounds get developed, and — in a crisis — which countries get supplied first.
The defenders of the status quo have a ready answer. The Economist has put it plainly: 'Diseases cross borders. So should their cures.' It is a reasonable-sounding principle. It is also the kind of principle that works only when every party at the table shares it. One of the sources in Bethany McLean's reporting for The Free Press framed the real question with more precision: it is not if China will weaponize its position in biotech, it is when.
That framing is not alarmism. It is the application of a lesson the United States has already learned — expensively — in semiconductors, in rare earth minerals, and in personal protective equipment during the early months of Covid-19. Each time, the vulnerability was visible in advance. Each time, the response came after the leverage had already been established.
The pharmaceutical case carries an additional dimension that makes it harder to dismiss. Drugs are not interchangeable commodities. A country that controls the origination of medicines for cancer, cardiovascular disease, or the next novel pathogen controls something closer to a biological chokepoint than a trade imbalance. The national security community has begun to notice; the broader public debate has not caught up.
What is missing is not information. The Morgan Stanley projection is public. The trajectory of Chinese investment in biotech is documented. What is missing is the political will to treat pharmaceutical supply chains with the same seriousness that the current administration has applied to steel tariffs or semiconductor export controls.
Follow the incentive, not the press release. Chinese state-backed firms are not investing in drug discovery because they believe in open science and borderless cures. They are investing because dominance in pharmaceuticals is the logical next chapter of an industrial strategy that has been consistent, patient, and largely successful for two decades.
The record on every prior industry is public. The question is whether Washington will read it before the leverage is already in place — or after.
